Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial

Cao, Yang, Wei, Jia, Zou, Liang, Jiang, Tiebin, Wang, Gaoxiang, Chen, Liting, Huang, Liang, Meng, Fankai, Huang, Lifang, Wang, Na, Zhou, Xiaoxi, Luo, Hui, Mao, Zekai, Chen, Xing, Xie, Jungang, Liu, Jing, Cheng, Hui, Zhao, Jianping, Huang, Gang, Wang, Wei, Zhou, Jianfeng·2020·Journal of Allergy and Clinical Immunology
DOI 10.1016/j.jaci.2020.05.019

Cited by (464)

Items 201–300 of 464

  1. COVID-19: Before the Fall, An Evidence-Based Narrative Review of Treatment Options
    Nicholas Rebold, Dana J. Holger, Sara Alosaimy, Taylor Morrisette, Michael Joseph Rybak · 2021 · Infectious Diseases and Therapy
  2. Calming the inflammatory storm in severe COVID-19 infections: Role of biologics- A narrative review
    David Banji, Saad S. Alqahtani, Otilia J.F. Banji, Shamna Machanchery, Ambreen Shoaib · 2021 · Saudi Pharmaceutical Journal
  3. Ruxolitinib and the Mitigation of Severe COVID-19: A Systematic Review and Meta-analysis
    Jorge Quiros, Jennifer Ross-Comptis, Donald Hathaway, Azza Sarfraz, Zouina Sarfraz, Zhanna Grigoryan, Kimberly Anne Romero, Abubakar Gapizov, Fortunato S. Príncipe-Meneses, Manoj Kumar Reddy Somagutta et al. · 2021 · Infection and Chemotherapy
  4. Executable network of SARS-CoV-2-host interaction predicts drug combination treatments
    Rowan S. M. Howell, Matthew A. Clarke, Ann‐Kathrin Reuschl, Tianyi Chen, Sean Abbott-Imboden, Mervyn Singer, David M. Lowe, Clare L. Bennett, Benny Chain, Clare L. Jolly et al. · 2022 · npj Digital Medicine
  5. Immune Signature of COVID-19: In-Depth Reasons and Consequences of the Cytokine Storm
    Paulina Niedźwiedzka‐Rystwej, Adam Majchrzak, Sara Kurkowska, Paulina Małkowska, Olga Sierawska, Rafał Hrynkiewicz, Miłosz Parczewski · 2022 · International Journal of Molecular Sciences
  6. Abstracts for reports of randomized trials of COVID-19 interventions had low quality and high spin
    Dongguang Wang, Lingmin Chen, Lian Wang, Fang Hua, Juan Li, Yuxi Li, Yonggang Zhang, Hong Song Fan, Weimin Li, Mike J Clarke · 2021 · Journal of Clinical Epidemiology
  7. Water resource rejuvenation via AOP based degradation of pharmaceuticals extensively used during COVID-19
    Vineeta Singh, Shashi Prakash Gupta, Sujoy Kumar Samanta · 2024 · Journal of Water Process Engineering
  8. Important Pharmacogenetic Information for Drugs Prescribed During the SARS‐CoV‐2 Infection (COVID‐19)
    Pablo Zubiaur, Dóra Koller, Miriam Saiz‐Rodríguez, Marcos Navares‐Gómez, Francisco Abad‐Santos · 2020 · Clinical and Translational Science
  9. Clinical trials in COVID-19 management & prevention: A meta-epidemiological study examining methodological quality
    Kimia Honarmand, J.B. Penn, Arnav Agarwal, Reed Alexander Cunningham Siemieniuk, Romina Brignardello‐Petersen, Jessica Julia Bartoszko, Dena Zeraatkar, Thomas Agoritsas, Karen E. A. Burns, Shannon M. Fernando et al. · 2021 · Journal of Clinical Epidemiology
  10. Ruxolitinib en COVID-19 grave
    Marcelo Iastrebner, Joaquín Castro, Edgardo García Espina, Carolina Kato Lettieri, Silvio Payaslián, María Celia Cuesta, Pablo Gutiérrez Fernández, Araceli Mandrile, Angela Paola Contreras, Sebastián Gervasoni et al. · 2021 · Revista de la Facultad de Ciencias Médicas de Córdoba
  11. Effects of Janus kinase inhibitors in adults admitted to hospital due to COVID-19: a systematic review and individual participant data meta-analysis of randomised clinical trials
    Alain Amstutz, Stefan Schandelmaier, Hannah Ewald, Benjamin Speich, Johannes M. Schwenke, Christof Schönenberger, Stephan Schobinger, Thomas Agoritsas, Kay Marie Tomashek, Seema Nayak et al. · 2025 · The Lancet Respiratory Medicine
  12. Phase I study in healthy participants to evaluate safety, tolerability, and pharmacokinetics of inhaled nezulcitinib, a potential treatment for COVID‐19
    Nathan D. Pfeifer, Arthur Lo, David L. Bourdet, Kenneth J. Colley, Dave Singh · 2021 · Clinical and Translational Science
  13. A panel of janus kinase inhibitors identified with anti-inflammatory effects protect mice from lethal influenza virus infection
    Yang Yu, Si Chen, Haonan Zhang, Yuanyuan Duan, Zhuogang Li, Lefang Jiang, Weihua Cao, Qun Peng, Xulin Chen · 2024 · Antimicrobial Agents and Chemotherapy
  14. Can Glycine Mitigate COVID-19 Associated Tissue Damage and Cytokine Storm?
    Chuan‐Yuan Li · 2020 · Radiation Research
  15. Compassionate use of ruxolitinib in patients with SARS‐Cov‐2 infection not on mechanical ventilation: Short‐term effects on inflammation and ventilation
    Andrea Mortara, Simone Mazzetti, Davide Margonato, Pietro Delfino, Chiara Bersano, Francesco Catagnano, Marinella Lauriola, Paolo Grosso, Gianluca Perseghin, Giovanbattista Ippoliti · 2021 · Clinical and Translational Science
  16. Evaluating the methodology of studies conducted during the global COVID-19 pandemic: A systematic review of randomized controlled trials
    Mengzhu Zhao, Chen Zhao, Shuang-shuang Tu, Xuxu Wei, Hongcai Shang · 2021 · Journal of Chinese Integrative Medicine
  17. Potential for jaktinib hydrochloride to treat cytokine storms in patients with COVID-19
    Xianmin Meng, Yun Ling, Li Zhang, Qian Zhang, Ping Dong, Tongyu Zhu, Hongzhou Lu · 2020 · BioScience Trends
  18. Reporting and design of randomized controlled trials for COVID-19: A systematic review
    Alison Dillman, Jay Park, Michael J. Zoratti, Noor-E Zannat, Zelyn Lee, Louis Dron, Grace G. Hsu, Gerald Smith, Sahand Khakabimamaghani, Ofir Harari et al. · 2020 · Contemporary Clinical Trials
  19. Ruxolitinib ameliorated coxsackievirus B3-induced acute viral myocarditis by suppressing the JAK-STAT pathway
    Liang Chen, Mengying Zhu, Gaoxiang Wang, Lili Lu, Lin Li, Lei Lei, Ting Wu · 2023 · International Immunopharmacology
  20. Exosomes-mediated transfer of LINC00691 regulates the formation of CAFs and promotes the progression of gastric cancer
    Bin Xia, Xiuyu Gu, Tingting Xu, Meina Yan, Lan Huang, Chun Jiang, Meifen Li, Guanghua Zhai, Guoping Zhang, Jian Wu et al. · 2023 · BMC Cancer
  21. Cytokine storm release syndrome and the prospects for immunotherapy with COVID-19, part 4: The role of JAK inhibition
    Leonard H. Calabrese, Tiphaine Lenfant, Cassandra M. Calabrese · 2020 · Cleveland Clinic Journal of Medicine
  22. Induction of the Antiviral Immune Response and Its Circumvention by Coronaviruses
    Ping Liu, Hong Yan, Bincai Yang, Prasha Shrestha, Nelam Sajjad, Ji‐Long Chen · 2020 · Viruses
  23. Hematological changes in patients with COVID‑19 (Review)
    Jieyu Ye, Yingying Jiao, Yujiao Zhang, Zongpeng Li, Xiaoyuan Zeng, Huixia Deng, Mo Yang · 2020 · Molecular Medicine Reports
  24. The management of hematologic malignancies during the COVID-19 pandemic
    Iwona Hus, Aleksander Salomon‐Perzyński, Krzysztof Tomasiewicz, Tadeusz Robak · 2020 · Expert Opinion on Pharmacotherapy
  25. COVID-19 Therapeutics for Low- and Middle-Income Countries: A Review of Candidate Agents with Potential for Near-Term Use and Impact
    Daniel N. Maxwell, Kelly C. Sanders, Oliver J. Sabot, Ahmad A. Hachem, Alejandro Llanos‐Cuentas, Ally Olotu, Roly Daniel Gosling, James B Cutrell, Michelle S. Hsiang · 2021 · American Journal of Tropical Medicine and Hygiene
  26. Integrative COVID-19 biological network inference with probabilistic core decomposition
    Yang Guo, Fatemeh Esfahani, Xiaojian Shao, Venkatesh Srinivasan, Alex Thomo, Li Xing, Xuekui Zhang · 2021 · Briefings in Bioinformatics
  27. Drug Interactions for Patients with Respiratory Diseases Receiving COVID-19 Emerged Treatments
    Marios Spanakis, Athina E. Patelarou, Evridiki Patelarou, Νikolaos Tzanakis · 2021 · International Journal of Environmental Research and Public Health
  28. Pharmacological mechanism of immunomodulatory agents for the treatment of severe cases of COVID-19 infection
    Zahra Bahari, Zohreh Jangravi, Hassan Ghoshooni, Mohammad Reza Afarinesh, Gholam Hossein Meftahi · 2021 · Inflammation Research
  29. The systemic pro-inflammatory response: targeting the dangerous liaison between COVID-19 and cancer
    Gino M Dettorre, M. Patel, Alessandra Gennari, George E. Pentheroudakis, Emanuela Romano, Alessio Cortellini, David James Pinato · 2021 · ESMO Open
  30. Ruxolitinib, a promising therapeutic candidate for traumatic brain injury through maintaining the homeostasis of cathepsin B
    Jianhang Peng, Cheng Hui Gao, Xueshi Chen, Tao Wang, Chengliang Luo, Mingyang Zhang, Xiping Chen, Luyang Tao · 2023 · Experimental Neurology
  31. Macrophage activation syndrome in Sepsis: from pathogenesis to clinical management
    Shunyao Chen, Cong Zhang, Jialiu Luo, Zhiqiang Lin, Teding Chang, Liming Dong, Deng Chen, Zhaohui Tang · 2024 · Inflammation Research
  32. Therapeutics for the Management of Cytokine Release Syndrome in COVID-19
    Rakesh Bhaskar, Jitendra Kumar Sinha, Shampa Ghosh, Shantanu Durgvanshi, Sung Soo Han · 2022 · Current Topics in Medicinal Chemistry
  33. Interleukin 6: A biomarker for COVID-19 progression
    El-houcine Sebbar, Mohammed Amine Choukri · 2022 · Materials Today Proceedings
  34. Targeted therapy in Coronavirus disease 2019 (COVID-19): Implication from cell and gene therapy to immunotherapy and vaccine
    Moein Shirzad, Marjan Nourigorji, Atefe Sajedi, Maryam Ranjbar, Faeze Rasti, Zahra Sourani, Mona Moradi, Seyed Mostafa Mir, Mohammad Yousef Memar · 2022 · International Immunopharmacology
  35. Incidence of Stroke in Randomized Trials of COVID-19 Therapeutics: A Systematic Review and Meta-Analysis
    Sanjana Nagraj, Dimitrios Varrias, Gabriel Hernández Romero, Heitor Tavares Santos, Dimitrios Karamanis, Dimitrios Sagris, Eleni Korompoki, Haralampos J. Milionis, Leonidas Palaiodimos, George Ntaios · 2022 · Stroke
  36. The protective effect of rheumatic disease agents in COVID-19
    Maria O Valenzuela-Almada, Michael Putman, Alí Duarte‐García · 2021 · Best Practice & Research Clinical Rheumatology
  37. Activated neutrophils in the initiation and progression of COVID-19: hyperinflammation and immunothrombosis in COVID-19.
    Xinyi Zhao, Lijin Zhou, Yan Kou, Junjie Kou · 2022 · PubMed Central
  38. Analysis of the correlation between anti-MDA5 antibody and the severity of COVID-19: a retrospective study
    Changzheng Liu, Qian Wang, Yeming Wang, Wang Geng, Linghang Wang, Hong Chen, Tao Jiao, Chaojun Hu, Xiaobo Lei, Li Guo et al. · 2020 · medRxiv
  39. SARS-CoV-2 pharmacologic therapies and their safety/effectiveness according to level of evidence
    Amanda Baroutjian, Carol Sanchez, Dessy Boneva, Mark McKenney, Adel Elkbuli · 2020 · The American Journal of Emergency Medicine
  40. Antivirális és gyulladásellenes kezelési lehetőségek COVID–19-ben
    Zoltán Szekanecz, Krisztina Bogos, Tamás Constantin, Béla Fülesdi, Veronika Müller, Éva Rákóczi, István Zsolt Várkonyi, Istvan T. Valyi-Nagy · 2021 · Orvosi Hetilap
  41. A Review of Treatment and Prevention of Coronavirus Disease 2019 among Solid Organ Transplant Recipients
    Deanna J. Buehrle, Robert R. Sutton, Erin L. McCann, AARON E. LUCAS · 2021 · Viruses
  42. Contemporary narrative review of treatment options for COVID ‐19
    Lianhan Shang, David Chien Lye, Bin Cao · 2021 · Respirology
  43. Successful ruxolitinib administration for a patient with steroid‐refractory idiopathic pneumonia syndrome following hematopoietic stem cell transplantation: A case report and literature review
    Dan Tomomasa, Takeshi Isoda, Noriko Mitsuiki, Motoi Yamashita, Aoi Morishita, Takahiro Tomoda, Tsubasa Okano, Akifumi Endo, Takahiro Kamiya, Masakatsu D. Yanagimachi et al. · 2021 · Clinical Case Reports
  44. Functional Genetics in Inborn Errors of Immunity
    Emma Rey-Jurado, M. Cecilia Poli · 2021 · Future Rare Diseases
  45. Cytokine Profile of Invasive Pulmonary Aspergillosis in Severe COVID-19 and Possible Therapeutic Targets
    Alessandro Russo, Helen Linda Morrone, Salvatore Rotundo, Enrico Maria Trecarichi, Carlo Torti · 2022 · Diagnostics
  46. Overview of Antiviral Drug Therapy for COVID-19: Where Do We Stand?
    Renata Esposito, Davida Mirra, Liberata Sportiello, Giuseppe Spaziano, Bruno D’Agostino · 2022 · Biomedicines
  47. Taming the Storm in the Heart: Exploring Different Therapeutic Choices Against Myocardial Inflammation in COVID-19
    Abhigyan Choudhury, Suprabhat Mukherjee · 2021 · Recent Advances in Anti-Infective Drug Discovery
  48. Rebalancing viral and immune damage versus repair prevents death from lethal influenza infection
    Hiroshi Ichise, Emily E. Speranza, Federica La Russa, Tibor Z. Veres, Colin J. Chu, Anita Gola, Beatrice Clark, Ronald N. Germain · 2025 · Science
  49. Successfully treated severe COVID‐19 and invasive aspergillosis in early hematopoietic cell transplantation setting
    Manuela Spadea, Francesca Carraro, Francesco Saglio, Elena Vassallo, Rosanna Pessolano, Massimo Berger, Carlo Scolfaro, Sergio Grassitelli, Franca Fagioli · 2020 · Transplant Infectious Disease
  50. Coronavirus disease-2019 (COVID-19): value of IL-6 inhibitors
    Evgeny Lvovich Nasonov · 2020 · PULMONOLOGIYA
  51. Synthesis, Biological Validation, and Docking Studies of Novel Purine Derivatives Containing Pyridopyrimidine, Pyrazolopyridine, and Pyranonapthyridine Rings †
    Vaijinath A. Verma, Bharathi Halu, Anand R. Saundane, Rajkumar S. Meti · 2021 · Polycyclic aromatic compounds
  52. Screening of potential inhibitors of COVID-19 with repurposing approach via molecular docking
    Negin Alizadehmohajer, Abtin Behmardi, Simin Najafgholian, Shabnam Moradi, Forogh Mohammadi, Reza Nedaeinia, Shaghayegh Haghjooy Javanmard, Ehsan Sohrabi, Rasoul Salehi, Gordon A. Ferns et al. · 2022 · Network Modeling Analysis in Health Informatics and Bioinformatics
  53. Comparative efficacy and safety of pharmacological interventions for severe COVID-19 patients: An updated network meta-analysis of 48 randomized controlled trials
    Qinglin Cheng, Gang Zhao, Junfang Chen, Qingjun Jia, Zijian Fang · 2022 · Medicine
  54. A Narrative Review of Emerging Therapeutics for COVID-19
    Van C. Willis, Yull Edwin Arriaga, Dilhan Weeraratne, F. Leonardi Reyes, Gretchen Purcell Jackson · 2020 · Mayo Clinic Proceedings Innovations Quality & Outcomes
  55. Pharmacological considerations for the treatment of COVID-19 in people living with HIV (PLWH)
    María del Mar Gutiérrez, Isabel Mur, Gracia María Mateo, Francesc Vidal, Peré Domingo · 2021 · Expert Opinion on Pharmacotherapy
  56. Efficacy and safety of short-wave diathermy treatment for moderate COVID-19 patients: a prospective, double-blind, randomized controlled clinical study
    Fei TIAN, Jin WANG, Xiao XI, Xiaolong SUN, Miao HE, Chenguang ZHAO, Feng FENG, Hongbin WANG, Wei SUN, Li MAO et al. · 2022 · European Journal of Physical and Rehabilitation Medicine
  57. COVID-19-Associated acute respiratory distress syndrome (CARDS): Mechanistic insights on therapeutic intervention and emerging trends
    Komal Thapa, Nitin Verma, Thakur Gurjeet Singh, Amarjot Kaur Grewal, Neha Kanojia, Lata Rani · 2021 · International Immunopharmacology
  58. Pyroptotic Patterns in Blood Leukocytes Predict Disease Severity and Outcome in COVID-19 Patients
    Yingkui Tang, Peidong Zhang, Qiuyu Liu, Luyang Cao, Jingsong Xu · 2022 · Frontiers in Immunology
  59. Molecules inhibit the enzyme activity of 3-chymotrypsin-like cysteine protease of SARS-CoV-2 virus: the experimental and theory studies
    Zhesheng He, Wencong Zhao, Wenchao Niu, Xuejiao Gao, Xingfa Gao, Yong Gong, Xueyun Gao · 2020 · bioRxiv (Cold Spring Harbor Laboratory)
  60. JAK-Inhibitor and Type I Interferon Ability to Produce Favorable Clinical Outcomes in COVID-19 Patients: A Systematic Review and Meta-Analysis
    Lucas Walz, Avi J. Cohen, Andre P. Rebaza, James Vanchieri, Martin D. Slade, Charles S. Dela Cruz, Lokesh Sharma · 2020 · Research Square
  61. Quality of reporting of adverse events in clinical trials of covid-19 drugs: systematic review
    Karima Madi, Clara Flumian, Pascale Olivier, Agnès Sommet, François Montastruc · 2023 · BMJ Medicine
  62. Transient prenatal ruxolitinib treatment suppresses astrogenesis during development and improves learning and memory in adult mice
    Han-Chung Lee, Hamizun Hamzah, Melody Pui-Yee Leong, Hadri Hadi Md Yusof, Omar Habib, Shahidee Zainal Abidin, Eryse Amira Seth, Siong Meng Lim, Sharmili Vidyadaran, Mohamad Aris Mohd Moklas et al. · 2021 · Scientific Reports
  63. Design, synthesis, and biological evaluation of novel ruxolitinib and baricitinib analogues for potential use against COVID‐19
    Qin Lin, Jun Li, Yinping Wang, Jie Zang · 2022 · Chemical Biology & Drug Design
  64. In silico study of novel niclosamide derivatives, SARS-CoV-2 nonstructural proteins catalytic residue-targeting small molecules drug candidates
    Bashir Lawal, Sheng-Kuang Tsai, Alexander T.H. Wu, Hsu‐Shan Huang · 2023 · Arabian Journal of Chemistry
  65. Recognition of Differentially Expressed Molecular Signatures and Pathways Associated with COVID-19 Poor Prognosis in Glioblastoma Patients
    Faisal A. Alzahrani, Mohd Faheem Khan, Varish Ahmad · 2023 · International Journal of Molecular Sciences
  66. COVID-19 Antiviral and Treatment Candidates: Current Status
    Erica Españo, Dajung Kim, Ji‐Yeon Kim, Song‐Kyu Park, Jeong-Ki Kim · 2021 · Immune Network
  67. A comprehensive review of adverse events to drugs used in COVID‐19 patients: Recent clinical evidence
    Renato Ferreira‐da‐Silva, Inês Ribeiro‐Vaz, Manuela Morato, Jorge Junqueira Polónia · 2022 · European Journal of Clinical Investigation
  68. Etoricoxib may inhibit cytokine storm to treat COVID-19
    Ruo Wang · 2021 · Medical Hypotheses
  69. Toward a Coronavirus Knowledge Graph
    Peng Zhang, Yi Bu, Peng Jiang, Xiaowen Shi, Bing Lun, Chongyan Chen, Arida Ferti Syafiandini, Ying Ding, Min Song · 2021 · Genes
  70. JAK Inhibition with Ruxolitinib in Patients with COVID-19 and Severe Pneumonia: Multicenter Clinical Experience from a Compassionate Use Program in Italy
    Alessandro Maria Vannucchi, Andrea Mortara, A. D’Alessio, Mara Morelli, Alberto Tedeschi, Moreno Benedetto Festuccia, Antonella d’Arminio Monforte, Enrico Capochiani, Carmine Selleri, Federico Simonetti et al. · 2021 · Journal of Clinical Medicine
  71. An Overview of SARS-CoV-2 Potential Targets, Inhibitors, and Computational Insights to Enrich the Promising Treatment Strategies
    Pooja Kumawat, Lokesh Kumar Agarwal, Kuldeep Raj Sharma · 2024 · Current Microbiology
  72. Illuminating the pathogenic role of SARS-CoV-2: Insights into competing endogenous RNAs (ceRNAs) regulatory networks
    Mahsa Aghajani Mir · 2024 · Infection Genetics and Evolution
  73. Janus kinase inhibitors for hospitalized patients with COVID-19: a meta-analysis of randomized controlled trials
    Shao‐Huan Lan, Chiung-Kai Wang, Shen-Peng Chang, Li‐Chin Lu, Shun‐Hsing Hung, Wei‐Ting Lin · 2021 · Expert Review of Anti-infective Therapy
  74. JAK Inhibitors in Cytokine Storm Syndromes
    Camille Keenan, Sabrin Albeituni, Kim E. Nichols, Melissa Hines · 2024 · Advances in experimental medicine and biology
  75. Response to pegylated interferon in a COVID‐19–positive elderly woman with primary myelofibrosis treated with ruxolitinib
    Arthur Edward Frankel, Renuka Reddy, Kayla R DeSuza, Khaled Deeb, Aaron F. Carlin, Davey Smith, Yushuang Xie, Eknath Naik, Richard T. Silver, Hans Carl Hasselbalch · 2021 · Clinical Case Reports
  76. SARS-CoV-2 Induced Neurological Manifestations Entangles Cytokine Storm that Implicates for Therapeutic Strategies
    Zhao-Zhong Chong, Nizar Souayah · 2021 · Current Medicinal Chemistry
  77. Therapeutic Options for Coronavirus Disease 2019 (COVID-19): Where Are We Now?
    Esther Y. Golnabi, James M. Sanders, Meagan L. Johns, Kevin Lin, Jessica K. Ortwine, Wenjing Wei, Norman S. Mang, James B Cutrell · 2021 · Current Infectious Disease Reports
  78. Review of Anti-inflammatory and Antiviral Therapeutics for Hospitalized Patients Infected with Severe Acute Respiratory Syndrome Coronavirus 2
    Jen‐Ting Chen, Marlies Ostermann · 2022 · Critical Care Clinics
  79. COVID-19 Impact on Chronic Myeloid Leukemia Patients
    Dana Raluca Arbore, Simona Maria Galdean, Delia Monica Dima, Ioana Rus, Dávid Kegyes, Raluca Geanina Ababei, Daniela Dragancea, Radu Andrei Tomai, Adrian Pavel Trifa, Ciprian Tomuleasa · 2022 · Journal of Personalized Medicine
  80. Case report: Optimized ruxolitinib-based therapy in an infant with familial hemophagocytic lymphohistiocytosis type 3
    Daiki Niizato, Takeshi Isoda, Noriko Mitsuiki, Shuya Kaneko, Dan Tomomasa, Takahiro Kamiya, Masatoshi Takagi, Kohsuke Imai, Michiko Kajiwara, Masaki Shimizu et al. · 2022 · Frontiers in Immunology
  81. Chest CT Features of 182 Patients with Mild Coronavirus Disease 2019 (COVID-19) Pneumonia: A Longitudinal, Retrospective and Descriptive Study
    Huaping Liu, Shiyong Luo, Youming Zhang, Yuzhu Jiang, Yuting Jiang, Yayi Wang, Hailan Li, Chi-Yao Huang, Shunzhen Zhang, Xili Li et al. · 2020 · Infectious Diseases and Therapy
  82. Analysis of the performances of the Covid-19 therapeutic approaches in the United Arab Emirates
    Alberto A. Boretti · 2021 · Signa Vitae
  83. Neutralizing Anti-interferon-γ Autoantibodies: an Ameliorating Factor in COVID-19 Infection?
    Mark Kačar, Paulina Cortes-Acevedo, Vinesh Patel, Clive R.D. Carter, Pamela J. Hughes, Hugh McGann, Effrossyni Gkrania‐Klotsas, Helen Baxendale, Gabriela Barcenas‐Morales, Rainer Döffinger et al. · 2021 · Journal of Clinical Immunology
  84. SYSTEMATIC REVIEW: EVALUATION OF CYTOKINE STORM TREATMENT FROM COVID 19 PATIENT BASE ON CLINICAL TRIAL
    NINDI ARNANDA, Diana Laila Ramatillah · 2022 · International Journal of Applied Pharmaceutics
  85. COVID 19 pandemic challenges and their management: A review of medicines, vaccines, patents and clinical trials with emphasis on psychological health issues
    Sradhanjali Mohapatra, P. Ayash Kumar, Uzma Farooq, Pooja Jain, Rahmuddin Khan, Nazia Hassan, Athar Shamim, Mohammad Javed Ansari, Ahmed S. Alalaiwe, Mohammed F. Aldawsari et al. · 2022 · Saudi Pharmaceutical Journal
  86. Beyond suppression: the paradox of JAK inhibitors as amplifiers of cancer immunotherapy
    Jaroslav Žák, John Ross Teijaro · 2026 · Nature reviews. Immunology
  87. Anti-rheumatic drugs as potential anti-inflammatory, immunomodulatory agents against COVID-19: A systematic review
    Reza Sinaei, Sara Pezeshki, Ali Asadipour, Reza Shiari, Roya Sinaei, Ali Sinaei · 2021 · Pharmaceutical Sciences
  88. JAK inhibitors dampen activation of interferon-activated transcriptomes and the SARS-CoV-2 receptor ACE2 in human renal proximal tubules
    Jakub Jankowski, Hye‐Kyung Lee, Julia Wilflingseder, Lothar G. Hennighausen · 2021 · iScience
  89. Effect of JAK Inhibitors on the Risk of Death in Patients with Moderate to Severe COVID-19: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
    Chia Siang Kow, Dinesh Sangarran Ramachandram, Syed Shahzad Hasan · 2024 · The Canadian Journal of Hospital Pharmacy
  90. An Updated Systematic Review and Network Meta-Analysis of 25 Randomized Trials Assessing the Efficacy and Safety of Treatments in Covid-19 Disease
    Alhassane Diallo, Miguel Carlos‐Bolumbu, Traoré Marie, Mamadou Diallo, Christophe Jedrecy · 2021 · Journal of Public Health Research
  91. Advances in clinical outcomes: What we have learned during the COVID-19 pandemic
    Amer Al-Musa, Brenna LaBere, Saddiq B. Habiballah, Alan A. Nguyen, Janet S. Chou · 2021 · Journal of Allergy and Clinical Immunology
  92. An insight into SARS-CoV-2 structure, pathogenesis, target hunting for drug development and vaccine initiatives
    Arijit Ghosh, Paritosh K. Kar, Anupam Gautam, Rahul Kumar Gupta, Rajveer Singh, Rudra Chakravarti, V. Ravichandiran, Shubhra Ghosh Dastidar, Dipanjan Ghosh, Syamal Roy · 2022 · RSC Medicinal Chemistry
  93. Evaluating Risk: Benefit Ratio of Fat-Soluble Vitamin Supplementation to SARS-CoV-2-Infected Autoimmune and Cancer Patients: Do Vitamin–Drug Interactions Exist?
    Radwa Y. Mekky, Noha Mousaad Elemam, Omar Eltahtawy, Yousra Ahmed Zeinelabdeen, Rana Ahmed Youness · 2022 · Life
  94. Whether the timing of patient randomization interferes with the assessment of the efficacy of ruxolitinib for severe COVID-19
    Hailan Li, Huaping Liu · 2020 · Journal of Allergy and Clinical Immunology
  95. Role of baricitinib in COVID-19 patients: A systematic review and meta-analysis
    Manisha Thakur, Akhil Babu, Gopal Lal Khatik, Ashok Kumar Datusalia, Ramchander Khatri, Anoop Kumar · 2023 · World Journal of Meta-Analysis
  96. Randomized phase II clinical trial of ruxolitinib plus simvastatin in COVID19 clinical outcome and cytokine evolution
    Jesús García-Donás, Diego Martínez‐Urbistondo, Kyra Velázquez‐Kennedy, Paula Villares, Arántzazu Barquín, Andrea Domínguez, Juan Francisco Rodríguez-Moreno, Elena Caro, Rafael Suárez del Villar Carrero, Estanislao Nistal‐Villán et al. · 2023 · Frontiers in Immunology
  97. Effect of tofacitinib on clinical and laboratory findings in severe and resistant patients with COVID-19
    Simin Almasi, Azadeh Rashidi, Manizhe Ataee Kachuee, Bentolhoda Mohammad Shirazi, Shirin Izadi, Sara Ghaffarpour, Mehdi Azimi, Mohammad Mehdi Naghizadeh, Mahin Jamshidi Makiani, Mitra Ranjbar et al. · 2023 · International Immunopharmacology
  98. Immunomodulatory drug therapy for the disease caused by SARS-CoV-2 infection (COVID-19)
    Dmitry Evgenyevich Karateev, Е. Л. Лучихина · 2020 · Almanac of Clinical Medicine
  99. Evolution of Clinical Care in COVID-Infected Solid Organ Transplant Recipients
    Rachel Sigler, Victor Chen, Nancy Law · 2022 · Current Transplantation Reports
  100. SARS‐CoV‐2 in digital era: Diagnostic techniques and importance of nucleic acid quantification with digital PCRs
    Neeraj Kumar, S. Aradhana, Harleen, Mangalathu Rajan Vishnuraj · 2023 · Reviews in Medical Virology